High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Blood

Volumn 117, Issue 8, 2011, Pages 2433-2440

  Kießling, Michael K ^a   Oberholzer, Patrick A ^b,c,d   Mondal, Chandrani ^c   Karpova, Maria B ^d   Zipser, Marie C ^d   Lin, William M ^e   Girardi, Michael ^e   MacConaill, Laura E ^b,c   Kehoe, Sarah M ^c   Hatton, Charlie ^b,c   French, Lars E ^d   Garraway, Levi A ^b,c   Polier, Gernot ^a   Süss, Dorothee ^a   Klemke, Claus Detlev ^f   Krammer, Peter H ^a   Gülow, Karsten ^a   Dummer, Reinhard ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAS PROTEIN; SELUMETINIB; SMALL INTERFERING RNA; UO 126;

ADULT; AGED; APOPTOSIS; ARTICLE; CASE REPORT; CELL GROWTH; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MALE; MASS SPECTROMETRY; MELANOMA; MYCOSIS FUNGOIDES; ONCOGENE RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEZARY SYNDROME; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN LYMPHOMA; SOMATIC MUTATION; T CELL LYMPHOMA; WESTERN BLOTTING;

EID: 79952182407     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-305128     Document Type: Article

References (50)

1. Shin J, Monti S, Aires DJ, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007;110(8):3015-3027. (Pubitemid 350006956)
2. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113(1):127-136.
3. Caprini E, Cristofoletti C, Arcelli D, et al. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. Cancer Res. 2009;69(21):8438-8446.
4. Carbone A, Bernardini L, Valenzano F, et al. Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/ DIABLO, and RHOF. Genes Chromosomes Cancer. 2008;47(12):1067-1075.
5. Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res. 2008; 68(8):2689-2698. (Pubitemid 351556266)
6. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869-873.
7. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006;12[suppl]:2366s-2370s.
8. Hersey P, Bastholt L, Chiarion-Sileni V, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol. 2009;20[suppl 6]:vi35-vi40.
9. Welcome Trust Sanger Institute. Catalogue of Somatic Mutations in Cancer. BRAF mutations in cancer. www.sanger.ac.uk/perl/genetics/CGP/ cosmic?action=bygene&ln=BRAF&start=&end=&coords=AA%3AAA. Accessed July 20, 2010.
10. Welcome Trust Sanger Institute. Catalogue of Somatic Mutations in Cancer. KRAS mutations in cancer. www.sanger.ac.uk/perl/genetics/CGP/ cosmic?action=bygene&ln=KRAS&start=&end=&coords=AA%3AAA. Accessed July 20, 2010.
11. Welcome Trust Sanger Institute. Catalogue of Somatic Mutations in Cancer. NRAS mutations in cancer. www.sanger.ac.uk/perl/genetics/CGP/ cosmic?action=bygene&ln=NRAS. Accessed July 20, 2010.
12. Mordant P, Loriot Y, Leteur C, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010;9(2):358-368.
13. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041-3046. (Pubitemid 351723664)
14. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
15. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
16. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hydsulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16(5):1613-1623.
17. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010; 16(8):2450-2457.
18. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res. 2010;16(3):1058-1064.
19. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or 2 prior chemotherapeutic regimens. Invest New Drugs. 2010 Feb 2 [Epub ahead of print].
20. Dummer R, Robert C, Chapman B, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol. 2008;26:Abstract 9033.
21. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
22. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347-351. (Pubitemid 46328493)
23. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(6):1713-1722. (Pubitemid 47443880)
24. Meyer JC, Hassam S, Dummer R, et al. A realistic approach to the sensitivity of PCR-DGGE and its application as a sensitive tool for the detection of clonality in cutaneous T-cell proliferations. Exp Dermatol. 1997;6(3):122-127. (Pubitemid 27235207)
25. Walczak H, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci. 2001;26(7): 452-453. (Pubitemid 32607488)
26. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008;14(8):2249-2252.
27. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007; 6(8):2209-2219. (Pubitemid 47294749)
28. Legrier ME, Yang CP, Yan HG, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007; 67(23):11300-11308.
29. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-2146.
30. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76(6):1214-1219. (Pubitemid 20318167)
31. Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68(16):6803-6809.
32. Sabnis AJ, Cheung LS, Dail M, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009;7:e59.
33. Tosca A, Linardopoulos S, Malliri A, Hatziolou E, Nicolaidou A, Spandidos DA. Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides. Anticancer Res. 1991;11(4): 1433-1438.
34. Zhang C, Toulev A, Kamarashev J, Qin JZ, Dummer R, Dobbeling U. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sezary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol. 2007;38(7):995-1002. (Pubitemid 46899153)
35. Rubinstein E. The untold story of HUT78. Science. 1990;248(4962):1499- 1507.
36. Gazdar AF, Carney DN, Bunn PA, et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood. 1980;55(3):409-417. (Pubitemid 10148261)
37. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001; 85(5):692-696.
38. Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4603-4609.
39. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600-608. (Pubitemid 351601205)
40. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007;104(21):8953-8958. (Pubitemid 47175418)
41. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-362. (Pubitemid 43128863)
42. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One. 2009; 4(5):e5717.
43. Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J Invest Dermatol. 2002;118(3):493-499. (Pubitemid 34227167)
44. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886-3896. (Pubitemid 46218691)
45. Mao X, Orchard G, Vonderheid EC, et al. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol. 2006;126(6):1388-1395. (Pubitemid 43997923)
46. Karenko L, Hahtola S, Paivinen S, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res. 2005;65(18):8101-8110. (Pubitemid 41330572)
47. Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood. 2000;95(9):2937-2942. (Pubitemid 30235906)
48. Utikal J, Poenitz N, Gratchev A, et al. Additional Her 2/neu gene copies in patients with Sezary syndrome. Leuk Res. 2006;30(6):755-760.
49. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med. 2003;197(11):1477-1488. (Pubitemid 36682545)
50. Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006; 12(16):4812-4821. (Pubitemid 44338565)